SOW
RLMD icon

State of Wyoming’s Relmada Therapeutics RLMD Stock Holding History

State of Wyoming’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142K Buy
20,586
+8,005
+64% +$55.9K 0.01% 1223
2026
Q1 		$87.6K Buy
+12,581
New +$59.5K 0.01% 1322
2022
Q3 		– Sell
-42
Closed -$1K – 1875
2022
Q2 		$1K Buy
42
+10
+31% +$218 ﹤0.01% 1815
2022
Q1 		$1K Buy
+32
New +$662 ﹤0.01% 1745
2021
Q4 		– Sell
-5
Closed – – 1961
2021
Q3 		$0 Buy
+5
New +$134 ﹤0.01% 1318

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

State of Wyoming's RLMD Position: Q2 2026 in Review

State of Wyoming increased its Relmada Therapeutics (RLMD) stake by 64% in Q2 2026, buying an estimated $55.9K and bringing the position to 20,586 shares worth $142K. The position accounts for 0.01% of the portfolio, ranked #1223.

State of Wyoming first reported a position in RLMD in Q3 2021 and has held it in 5 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • State of Wyoming held 20,586 shares of Relmada Therapeutics worth $142K as of Q2 2026.
  • State of Wyoming bought 8,005 Relmada Therapeutics shares in Q2 2026, an estimated $55.9K.
  • Relmada Therapeutics made up 0.01% of State of Wyoming's portfolio in Q2 2026, its #1223 holding.
  • State of Wyoming first reported a position in Relmada Therapeutics in Q3 2021 and has held it in 5 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on State of Wyoming's 13F filing for Q2 2026, filed 6 Aug 2026.